When will the FDA approve Compass Pathways' COMP360 Psilocybin?

Prediction market on kalshi. If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Oct 1, 2027, then the market resolves to Yes.

Liquidity: $1,111.72. Resolves: 10/8/2027.